And so when we discuss accessibility issues, especially for folks that are in the marginalized communities, then we have to be looking at data like this, and meeting those patients, like I said, where theyre at, but tell me what you think, Robert, what should we take away
Thus, preference should be given to molecules with the highest potency, such as semaglutide and dulaglutide, over those with lower potency, like exenatide
But GLP-1s are still not the solution for diabetes and obesity crises in our country. Appetite has a new name: food noise How exactly does a Glucagon-like-Peptides-1 (GLP-1) receptor agonist work
Narrow carve-outs apply, including members under 21 through EPSDT and non-obesity uses such as cardiovascular disease or obstructive sleep apnea
If yes, coverage is possible